advantage with this approach has not been demonstrated yet, at least in prospective randomised trials [3] [4] [5] [6] [7] .
In the past few years, there has been a renewed interest about the role of platinum compounds in the treatment of patients with breast cancer. Platin-and taxane-based primary chemotherapy has proven to be highly effective in patients with either large operable or locally advanced disease [8] [9] [10] [11] [12] . Experimental data suggest that triple-negative tumours may be highly sensitive to platinum-based chemotherapy [13] .
In the mid-1990s, we started the evaluation of a weekly triplet regimen including cisplatin, epirubicin, and paclitaxel (PET) in patients with breast cancer [14] [15] [16] [17] [18] in 1999, it compared 12 weekly cycles of PET with 4 triweekly cycles of epirubicin-paclitaxel (ET) in LABC patients. The pCR was the primary end point. We had set as 5% the pCR rate expected with the administration of ET, and hypothesised a 10% increase with the PET regimen. To have an 80% power to demonstrate such a difference with an alpha error <5%, at least 90 patients per arm were required. The accrual was stopped in November 2004, when 200 patients (100 PET and 100 ET) had been enrolled. Data were analysed in March 2005, when all data on pathologically documented response (pathological response) were available. The PET regimen yielded a significantly higher rate of pCRs. A preliminary evaluation of the progression/relapse-free survival (RFS) in the two arms was also carried out, although the estimate was heavily biased by the high proportion of early-censored patients (median follow-up 39 months), the results of which have been reported previously [14] . In November 2008, an additional analysis was carried out, after 4 years had elapsed from the date of the last patient enrolled, and median follow-up was 74 (range 48-105) months; the results of this analysis are reported in this article.
subjects and methods

study population
Eligible patients were women with histologically proven LABC (T4a to d and/or N2-3), aged <75 years. Of the 200 patients enrolled, 100 were randomly assigned to weekly PET and 100 to triweekly ET treatments. In the previous study, information on Ki-67 score was not included, and data on hormone receptors and human epidermal growth factor receptor-2 (HER-2) status were missing for some patients. In the present analysis, the pretreatment specimens of patients without immunohistochemical information were reviewed, so that data on hormone receptors, Ki-67 score, grading, and HER-2 status are available for all 200 patients. The SICOG 9908 trial was approved by the independent ethical committees of the institutions involved, and all patients gave their written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
treatment
All eligible patients were randomly allocated to receive the following-PET: cisplatin 30 mg/m 2 , epirubicin 50 mg/m 2 , and paclitaxel 120 mg/m 2 , weekly for 12 cycles; recombinant human granulocyte colony-stimulating factor 300 lg/day was also given subcutaneously on days 3-5 of each week or epirubicin 90 mg/m 2 and paclitaxel 175 mg/m 2 (ET), once every 3 weeks for four cycles. Within 4 weeks from the end of chemotherapy, patients underwent surgery. Breast-sparing surgery was carried out whenever feasible. The surgery consisted of quadrantectomy together with standard level I and II axillary lymph node dissection. It was carried out in a total of 37 patients (PET 23 and ET 14) .
Four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) were administered after surgery to patients whose pathological assessment showed involvement of less than four axillary lymph nodes (including pCR). Overall, 68 PET and 51 ET patients received adjuvant CMF. Additional four cycles of cyclophosphamide, epidoxorubicin, and fluorouracil (FEC) cycles were also administered to those women showing involvement of four or more axillary nodes. Overall, four FEC cycles were administered to 32 PET and 49 ET patients.
After postoperative chemotherapy, breast and homolateral axilla irradiation was carried out in patients who underwent conservative surgery.
Chest wall and axilla irradiation was carried out in those who underwent mastectomy and had involvement of more than three axillary nodes; involvement of muscle, skin, and/or nipple; or G3 tumour at diagnosis. Supraclavicular fossa and internal mammary nodes were not included in the radiation field. Overall, post-mastectomy irradiation was carried out in 36 PET and 53 ET patients.
Hormone treatment was also given on completion of postoperative chemotherapy. Luteinizing hormone-releasing hormone analogue for 2 years together with tamoxifen for 5 years was administered in premenopausal women and 5-year tamoxifen in postmenopausal women. No patients with HER-2-positive tumour received adjuvant trastuzumab.
pathological tumour response
In the previous analysis, pathological response in the breast was scored according to the Chevallier's criteria [19] , and a class I to II response in the breast together with negative axilla was considered as pCR. Overall, only 22 of 200 patients had shown a pCR.
Pathological complete response is an anecdotic event in truly endocrineresponsive tumours. Nevertheless, a favourable long-term outcome is expected in estrogen receptor (ER)-positive patients with a small-sized tumour and less aggressive residual disease. In the present study, 120 of 200 patients were ER positive. In view of these considerations, the 2003 American Joint Committee on Cancer (AJCC) tumour-node-metastasis staging system after neoadjuvant chemotherapy was used in the present analysis, to evaluate the pathological response [20] .
other end points
The present analysis focused on RFS, distant metastasis-free survival (DMFS), and overall survival (OS). RFS was defined as the interval between random assignment to treatment and the occurrence of the earliest subsequent breast cancer event, i.e. first occurrence of local, regional, and distant breast cancer recurrences; clinically inoperable disease at the end of chemotherapy; and gross residual disease after surgery, whereas occurrences of contralateral breast cancer, second primary cancer, or death without evidence of recurrence were considered as censoring events. The DMFS was defined as the interval between random assignment to treatment and the first occurrence of distant breast cancer recurrences. OS was defined as the interval between random assignment to treatment and death regardless of aetiology.
statistical analysis
Analysis of outcome data was based on information received as of 30 November 2008. Simple log-rank tests [21] and Cox proportional hazards models [22] were used to make formal inferences about group comparisons, and Kaplan-Meier curves [23] were used to quantify the values of RFS, DMFS, and OS over time. A first Cox regression analysis was carried out to evaluate the effect of treatment after adjusting for the following baseline parameters: ER (<10% versus ‡10%), grading (I-II versus III), Ki-67 score (<25% versus ‡25%), and HER-2 status (positive versus negative). A further Cox regression analysis was carried out to evaluate the prognostic relevance of pathological response (stages 0, I, II, and III), after adjusting for the same baseline features. A final multivariate analysis was carried out in those patients who had a residual tumour in the breast at surgery, which included the pathological stage (I, II, III) and posttreatment biomarkers (HER-2 status, ER, grading, and Ki-67 score). Two alternative grade (I-II versus III, and I versus II-III) and Ki-67 score (<25% versus ‡25% and <10% versus ‡10%) dichotomies were chosen ( Figure 1) .
P values from Wald chi-square tests indicated the statistical significance of a factor after adjusting for the other factors. SPSS software version 10.1 (SPSS Inc., Chicago, IL) was used for all analyses.
results
patient characteristics
Baseline patient characteristics within the SICOG 9908 protocol are listed in Table 1 . One hundred and thirty-six patients had T4a to c, 47 inflammatory, and 17 N2 breast cancers. ER was positive in 120 and negative in 80 patients. Tumour grades were I, II, and III in 22, 68, and 110 patients, respectively. Ki-67 score was <10%, 10%-24%, and ‡25% in 41, 67, and 92 patients, respectively. Forty-four of the 200 patients were HER-2 positive. All patients with inoperable disease after chemotherapy, 1 of 10 patients with local recurrence, and 5 of 9 patients with regional recurrence subsequently developed distant metastasis. Table 3 panel A summarises the patient's outcome according to baseline features and treatment. PET significantly improved RFS in patients with grade III tumour (5-year RFS 58% versus 44%, P = 0.03; Figure 2D ). In this subset of patients, PET showed a non-statistically significant superiority, in both ER-positive (P = 0.15) and ER negative (P = 0.12) tumours ( Figure 3D) .
At multivariate analysis, PET treatment showed a favourable impact on RFS of borderline significance (P = 0.057). HER-2 positive status (P = 0.008) and grading III (P =0.05) were independently predictive of worse RFS (Table 4 
panel A).
distant metastasis-free survival. Overall, 81 distant metastases (PET 34 and ET 47) had occurred, 5-year DMFSs being 73% and 55% in PET and ET arms (P = 0.037), respectively ( Figure 2B ).
PET treatment significantly improved DMFS in patients with grade III (5-year DMFS 71% versus 45%, P = 0.01; Figure 2E ), ER-negative (5-year DMFS 74% versus 45%, P = 0.03; Figure  3B ), and Ki-67 score ‡25% (5-year DMFS 74% versus 47%, P =0.03) tumours (Table 3 panel A) . In patients with grade III tumour, PET treatment had the same prognostic impact, in both ER-positive (P = 0.08) and ER-negative (P = 0.08) tumours ( Figure 3E) .
At multivariate analysis, PET treatment independently predicted better DMFS (P = 0.018). HER-2 positive status was independently associated with worse DMFS (P = 0.02; Table 4 panel A).
overall survival. Death by any cause occurred in 70 patients (PET 29 and ET 41), the 5-year OSs being 82% and 69% (P = 0.07) in PET and ET, respectively ( Figure 2C ). PET treatment significantly improved OS in patients with grade III (5-year OS 78% versus 61%, P = 0.008; Figure 2F ) and Ki-67 score ‡25% (5-year OS 80% versus 64%, P = 0.02) tumours, whereas the advantage in ER-negative patients was of borderline significance (5-year OS 84% versus 67%, P = 0.06; Figure 3C and Table 3 panel A). In patients with grade III tumour, PET yielded a significantly better survival in ER-negative (5-year estimate: PET 81% versus ET 65%, P = 0.04; Figure 3F ).
At multivariate analysis, PET treatment independently predicted better OS (P = 0.03). HER-2 positive status was independently associated with worse OS (P = 0.03; Table 4 panel A).
outcome according to post-treatment features relapse-free survival. A total of 85 relapses occurred in the 186 patients who underwent surgery (Table 3 panel B) . Five-year RFSs were 73%, 71%, 64%, and 51%, in stages 0, I, II, and III, respectively.
Eight of 13 relapses, occurring in stage 0-I patients, were locoregional (3 ipsilateral breast cancer, 1 chest wall, 2 internal mammary, 2 supraclavicular). Two of three ipsilateral breast cancer occurred in women with inflammatory breast cancer who had undergone quadrantectomy. In patients who underwent radiation therapy, the supraclavicular fossa and internal mammary nodes had not been included in the radiotherapy fields.
At multivariate analysis, AJCC pathological stage was highly predictive of RFS (P = 0.002). Pretreatment HER-2 positive status independently predicted a worse RFS (P = 0.0003; Table 4 panel B).
Seventy-two breast cancer events occurred in the 150 patients with residual tumour in the breast. Five-year RFSs were 77% versus 53% in grade I versus grades II-III (P = 0.005), and 88% versus 51% in Ki-67 <10% versus ‡10% (P = 0.0007). The alternative dichotomies, grades I-II versus III and Ki-67 <25% versus ‡25%, had worse prognostic characteristics (data not At multivariate analysis, post-treatment grade I (P = 0.04), Ki-67 score <10% (P = 0.006), and HER-2 negative status (P = 0.002) independently predicted better RFS (Table 4 panel C).
distant metastasis-free survival. A total of 67 distant relapses occurred in the 186 patients who underwent surgery. Five-year DMFSs were 85%, 84%, 67%, and 52% in stages 0, I, II, and III, respectively (Table 3 panel B) . Stages 0 and I taken together had better DMFS than both stages II (P = 0.03) and III (P = 0.0004; Figure 4A ).
At multivariate analysis, the stage (P = 0.0003) and baseline HER-2 status (P =0.01) had an independent prognostic effect ( Table 4 panel B) .
Fifty-nine of the 150 patients with residual tumour in the breast experienced a distant metastasis. The 5-year DMFSs were 84% versus 55% in grade I versus grades II-III (P = 0.004; Figure 4B ) and 85% versus 56% in Ki-67 score <10% versus ‡10% (P = 0.001; Figure 4C ). Five-year DMFSs were 78% and 70% in stage III patients, with grade I or Ki-67 score <10% residual tumour, respectively. At multivariate analysis, post-treatment grade I (P = 0.03), Ki-67 score <10% (P = 0.03), and HER-2 negative status (P = 0.02) independently predicted better DMFS (Table 4 
panel C).
overall survival. A total of 56 deaths occurred in the 186 patients who underwent surgery. Five-year OSs were 95%, 89%, 83%, and 73% in stages 0, I, II, and III, respectively (Table 3 panel B). Stages 0 and I taken together had better OS than both stages II (P = 0.04) and III (0.0007; Figure 4D ).
At multivariate analysis, the pathological stage (P =0.0005) and baseline HER-2 status (P =0.03) had an independent prognostic effect (Table 4 
panel B).
Fifty-three deaths occurred in the 150 patients with residual tumour in the breast. The 5-year OSs were 95% versus 73% in grade I versus grades II-III (P = 0.0004; Figure 4E ) and 91% versus 74% in Ki-67 score <10% versus ‡10% (P = 0.01; Figure 4F ).
Five-year OSs in stage III patients, with grade I or Ki-67 score <10% residual tumour, were 86% and 75%, respectively.
At multivariate analysis, grade I (P = 0.006), Ki-67 score <10% (P = 0.04), and HER-2 negative status (P = 0.01) independently predicted better OS (Table 4 panel C).
discussion
In the previous analysis, the high proportion of early-censored patients (median follow-up of 39 months) heavily biased the RFS estimates in both arms [14] . In the present analysis, when median follow-up exceeded 6 years, 5-year RFSs were 64% and 53% for PET and ET, respectively (univariate P = 0.11, multivariate P = 0.057). Patients who received PET showed a significantly lower risk of distant metastasis [ET versus PET: hazard ratio (HR) = 1.71, 95% confidence interval (CI) 1.10-2.67, P = 0.02] and death (ET versus PET: HR = 1.70, 95% CI 1.18-2.14, P = 0.03). 
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In contrast to the higher number of distant relapses observed in ET arm, the locoregional rate of relapse was similar in the two arms (PET 13 and ET 11). The relevant number of locoregional recurrences in both arms could partially be due to the restrictive criteria for radiotherapy administration we adopted in our protocol, and the adoption of a conservative surgical approach in some women with inflammatory disease.
These data confirm that breast conservation should always be avoided in inflammatory breast cancer, and an accurate initial work-up, including 2-[fluorine-18]fluoro-2-deoxy-D-glucose-PET and dynamic magnetic resonance imaging, should be performed in stage IIIB patients, to rule out the presence of occult supraclavicular, infraclavicular, internal mammary, and distant metastases. Moreover, irradiation of both internal mammary and supraclavicular nodal regions should be mandatory in patients with stage IIIB disease at diagnosis, whatever is the pathological response after preoperative chemotherapy.
McGuire et al. [24] reported a 33% 10-year locoregional relapse rate in pCR patients with stage III disease at diagnosis, who had not received post-mastectomy radiotherapy.
The short duration of the treatment, the low single and cumulative dose of paclitaxel and epirubicin delivered, and the triweekly schedule adopted could make the ET combination of the present trial an inadequate primary approach in patients with LABC [25] [26] [27] [28] . In spite of that, the survival outcome of patients who received ET (5-year RFS and OS, 53% and 69%, respectively) appears comparable with that reported in other studies with longer and/or more aggressive treatments [2-4, 24, 25] . The administration of four cycles of postoperative chemotherapy in all patients together with hormone treatment in ER-positive patients may have had a role in improving the outcome in both arms of our study, but it is unlikely that it could have affected the prognosis in an unbalanced way since a higher number of ET patients received FEC, which is expected to be more effective than CMF.
In the present study, the 5-year OS of the 100 stage IIIB patients who received PET (82%) was similar to that observed in the T1-3 patients of the National Surgical Adjuvant Breast and Bowel Project Protocols B-27 trial [29] , and compares favourably with that reported in 119 IIIB patients treated with primary chemotherapy at the M.D. Anderson Cancer Center between 1997 and 2003 [25] .
The magnitude of the increment in pCR rate obtained with PET cannot explain the 18% higher 5-year DMFS we observed in this arm. Assuming that the survival outcome of pCRs was similar in the two arms, a much lower rate of distant relapse must be hypothesised in pathological stage I-III patients who had received PET (5-year DMFS 73% = 16 · 0.85 + 78 · 0.76) as compared with those treated with ET (5-year DMFS 55% = 6 · 0.85 + 86 · 0.58), perhaps due to a reduced malignant potential of distant tumour clones. Despite the very high pCR rate observed in HER-2-positive patients who received PET [14] , HER-2 positive status was independently predictive of worse survival outcome. Baseline HER-2 overexpression still predicted worse outcome, even after adjusting for pathological stage and biomarker profile of the residual tumour. Adjuvant trastuzumab was not administered to HER-2-positive patients, which could explain the higher rates of relapses and deaths observed in this group.
PET treatment was much better than ET for patients with high-grade tumours. The 5-year OS of grade III patients who received PET (81%) was similar to that reported in grade III T1 patients [30] . The large majority of patients with grade III tumour also exhibited high Ki-67 scores, which explains the better DMFS and OS that PET showed in patients with highly proliferating tumour. The Ki-67 ‡ 25% score, we chose, was suggested to be the optimal cut-off point to select tumours more sensitive to chemotherapy [31] .
PET treatment also showed a significantly better DMFS in ER-negative patients, whereas the differences in terms of RFS and OS were of borderline significance. In the present study, ER-negative patients of the PET arm had a 84% 5-year OS, as compared with a 64% 5-year OS reported in triple-negative patients treated at the M.D. Anderson Cancer Center with preoperative chemotherapy from 1985 to 2004. About 80% of these patients had T1-3 tumour [32] .
In patients with high-grade and ER-positive tumours, PET showed a DMFS advantage of borderline significance (P = 0.08), which suggests a reduction of the risk for distant relapse in patients with aggressive tumours, irrespective of their ER status.
The concurrent administration of weekly paclitaxel, cisplatin, and dose-dense epirubicin makes our regimen substantially different from the other neoadjuvant treatments. Several authors have recently hypothesised that the administration of platinum compounds [33] , weekly paclitaxel [28, 34] , high dose-intensity epirubicin [35] might improve prognosis in the basal subtype of breast cancer.
Patients with ER-positive/high-proliferation tumours have a very poor outcome with adjuvant tamoxifen treatment, irrespective of the level of ER expression, perhaps due to the weakly or absent estrogen-dependent growth of the tumour [36] . This subset of patients may be highly chemoresponsive. Estrogen-dependent proliferation is associated with the expression of microtubule-associated protein Tau. ER-positive patients with lower Tau messenger RNA expression are highly responsive to neoadjuvant chemotherapy [37] . Therefore, theoretically, a dose-dense, platinum-including primary chemotherapy might result, in these patients, in a risk reduction close to that reported with a dose-dense adjuvant chemotherapy in ER-negative patients [38] .
In the present study, patients with downstaging of the tumour to pathological stages 0 and I had significantly better DMFS and OS. Furthermore, patients with pathological stage II-III and post-treatment grade I or Ki-67 score <10% tumour had a highly favourable survival outcomes. The strong prognostic role of post-treatment grading and Ki-67 score has original article Annals of Oncology been confirmed in many trials [39] [40] [41] . PET treatment almost doubled the number of patients with pathological stages 0-I and significantly increased the number of patients with Ki-67 <10% residual tumour. The more pronounced biological changes in the breast tumour, induced by PET, could mirror its stronger efficacy in reducing the malignant potential of the distant tumour clones, which explains the much lower risk of distant relapse observed in PET patients with residual tumour after treatment.
In conclusion, 12 weekly PET cycles improve both DMFS and OS in LABC patients as compared with 4 triweekly ET cycles. The therapeutic advantage is mainly evident in aggressive tumours identified by high grade and Ki-67 score. This therapeutic advantage may be independent of ER status. Further randomised trials testing weekly PET in LABC patients with unfavourable biomarkers are warranted.
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